Detecting tumor-specific DNA in blood is already common clinical practice in cancer patients with known mutational profiles (e.g. EGFR-mutant lung cancer) and therapy will be adapted according to presence or absence of certain tumor-specific mutations. Here, EGFR is linked to lung carcinoma.